

CORRECTION

Open Access

Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

Franco Locatelli, Gerhard Zugmaier , Noemi Mergen, Peter Bader, Sima Jeha, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, Rupert Handgretinger, Benoit Brethon, Claudia Rossig and Christiane Chen-Santel

Correction to: *Blood Cancer Journal*
<https://doi.org/10.1038/s41408-020-00342-x>
published online 24 July 2020

CR in the first 2 cycles achieved MRD response. The article has now been corrected to state 57/69 (82.6%).

The original version of the article contained an error in Fig. 1b, which showed that 57/69 (78.3%) of patients with

Published online: 01 February 2021




Fig. 1